Pfizer Inc is developing tremelimumab, a fully human monoclonal IgG2 antibody against cytotoxic T-lymphocyte-associated antigen, for the potential intravenous treatment of cancer. Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
tremelimumab fully
8
fully human
8
human monoclonal
8
monoclonal igg2
8
igg2 antibody
8
treatment cancer
8
antibody ctla4
4
ctla4 potential
4
potential treatment
4
cancer pfizer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!